Last reviewed · How we verify

NCT05850117

Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p

Status unknown NA Last updated 9 May 2023
What this trial tests

NA trial testing esomeprazole, tripotassium dicitrate bismuthate, tetracycline and levofloxacin in Helicobacter Pylori Eradication in 240 participants. Status unknown.

Timeline
10 February 2020
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorKaohsiung Medical University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment240
Start date10 February 2020
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Kaohsiung Medical University

Who can join

20 and older, any sex, with Helicobacter Pylori Eradication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Compare the efficacy of "Tetracycline combined with levofloxacin quadruple therapy", "standard tincture quadruple therapy" and "amoxicillin combined with levofloxacin quadruple therapy" on the second line of Helicobacter pylori sterilization. 2. To investigate the drug resistance of Helicobacter pylori and the host genotypes of CYP2C19 and IL-1B-511 on the sterilizing effect of three second-line Helicobacter pylori.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Helicobacter Pylori Eradication

Currently open trials in the same condition.

Other Kaohsiung Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05850117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing